A Phase 1 interventional study of Placebo and RO4917838 in Schizophrenia, sponsored by Hoffmann-La Roche. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-02.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Schizophrenia by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Schizophrenia · Hoffmann-La Roche.
Among the 19 studies in Schizophrenia by Hoffmann-La Roche, this one is the 15th largest by enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2010, is one of 5 in phase 1, and was the 2nd registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →None of the 19 studies in Schizophrenia by Hoffmann-La Roche is open now. The open studies under Schizophrenia, anywhere →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 6 started in 2010.
This study's enrollment of 29 is below the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 294 across the 16 interventional studies, 1,431 across the 3 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Schizophrenia by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, placebo-controlled parallel group study will assess the effect on biomarkers measures of cognitive dysfunction, the clinical efficacy and safety of RO4917838 in participants with schizophrenia and schizoaffective disorder. Participants will be randomized to receive either RO4917838 (10 milligrams [mg] daily orally) or placebo for 6 weeks, in addition to their stable antipsychotic medication. Anticipated time on study treatment is 6 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Placebo · Drug: Standard Antipsychotic Therapy
Drug: RO4917838 · Drug: Standard Antipsychotic Therapy
Orally daily for 6 weeks
10 mg daily orally for 6 weeks
Participants will continue to receive their current antipsychotic treatment (as they are receiving at the time of screening). Protocol does not specify any particular standard antipsychotic therapy.
Change From Baseline in Cognitive Dysfunction Biomarker (Mismatch Negativity) at Week 6, as Measured Using Electroencephalography (EEG)
Time frame: Baseline, Week 6
Change From Baseline in Cognitive Dysfunction Biomarker (Visual Event-Related Potential [ERP]) at Week 6, as Measured Using EEG
Time frame: Baseline, Week 6
Change From Baseline in Cognitive Dysfunction Biomarker (N1 Refractoriness) at Week 6, as Measured Using EEG
Time frame: Baseline, Week 6
Change From Baseline in Cognitive Dysfunction Biomarker (P3 Component) at Week 6, as Measured Using EEG
Time frame: Baseline, Week 6
Change From Baseline in Cognitive Dysfunction Biomarker (Visual Evoked Potential [VEP]) at Week 6, as Measured Using EEG
Time frame: Baseline, Week 6
Change From Baseline in Cognitive Dysfunction Biomarker (Mismatch Negativity) at Week 1, as Measured Using EEG
Time frame: Baseline, Week 1
Change From Baseline in Cognitive Dysfunction Biomarker (Visual Event-Related Potential [ERP]) at Week 1, as Measured Using EEG
Time frame: Baseline, Week 1
Change From Baseline in Cognitive Dysfunction Biomarker (N1 Refractoriness) at Week 1, as Measured Using EEG
Time frame: Baseline, Week 1
Change From Baseline in Cognitive Dysfunction Biomarker (P3 Component) at Week 1, as Measured Using EEG
Time frame: Baseline, Week 1
Positive Predictive Value of Cognitive Dysfunction Biomarkers (Mismatch Negativity, ERP, N1 Refractoriness, P3 Component, and VEP) Change at Week 1 to Predict the Presence of Biomarker Response at Week 6, as Measured Using EEG
Time frame: Baseline, Weeks 1 and 6
Positive Predictive Value of Cognitive Dysfunction Biomarkers (Mismatch Negativity, ERP, N1 Refractoriness, P3 Component, and VEP) Change at Week 1 to Predict the Change in Symptoms at Week 6, as Measured Using EEG
Time frame: Baseline, Weeks 1 and 6
Change From Baseline in Positive and Negative Syndrome Scale Score
Time frame: Baseline, Weeks 1, 3, and 6
Change From Baseline in Negative Symptom Assessment Score
Time frame: Baseline, Weeks 1, 3, and 6
Change From Baseline in Clinical Global Impression Scale
Time frame: Baseline, Weeks 1, 3, and 6
Change From Baseline in Calgary Depression Scale Score
Time frame: Baseline, Weeks 1, 3, and 6
Change From Baseline in Global Assessment of Functioning Score
Time frame: Baseline, Weeks 1, 3, and 6
Change From Baseline in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Cognition Battery Score
Time frame: Baseline, Weeks 1, 3, and 6
Change From Baseline in Cognitive Dysfunction Biomarker (Visual Evoked Potential [VEP]) at Week 1, as Measured Using EEG
Time frame: Baseline, Week 1
The record gives a start of Nov 2010, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bitopertin